Ask an Expert

Question of the Day

Schahram Akbarian, M.D., Ph.D. Scientific Council Member 1993, 2000 NARSAD Young Investigator Grantee 1997 Klerman Prizewinner Professor of Psychiatry and Neuroscience Chief of the Division of Psychiatric Epigenomics Mount Sinai School of Medicine, expert on autism
January 16, 2013

Presently, our findings have no implications yet for early diagnosis and treatment. Like all other research, our findings will have to await replication and confirmation by independent research groups. Furthermore, we studied brain specimens that were provided by the Autism Tissue Program. To find out whether our findings in the brain specimens are useful for early diagnosis and treatment, we would first need to find out if there are similar epigenetic signatures of disease in blood or skin cells that then could be tested in a clinical setting.

Schahram Akbarian, M.D., Ph.D.
Scientific Council Member
1993, 2000 NARSAD Young Investigator Grantee
1997 Klerman Prizewinner
Professor of Psychiatry and Neuroscience
Chief of the Division of Psychiatric Epigenomics
Mount Sinai School of Medicine

TAGS: Autism
Fred R. Volkmar, M.D.
Q What would ‘recovery’ from Autism be like?
A “They’re headed to a path of being independent and self sufficient as... More >
Schahram Akbarian, M.D., Ph.D. Scientific Council Member 1993, 2000 NARSAD Young Investigator Grantee 1997 Klerman Prizewinner Professor of Psychiatry and Neuroscience Chief of the Division of Psychiatric Epigenomics Mount Sinai School of Medicine, expert on autism
Q With regard to your research finding of an epigenetic signature of autism, can you tell me what this means for early diagnosis and treatment?
A Presently, our findings have no implications yet for early diagnosis and... More >